Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikhail Sumin

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
JACC. Heart Failure|March 5, 2023
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled AnalysisJoão Pedro Ferreira, Faiez Zannad, Javed Butler, et al.
American Heart Journal|May 20, 2022
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trialJosephine Harrington, Jacob A Udell, W Schuyler Jones, et al.
European Heart Journal|August 26, 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programmeFaiez Zannad, João Pedro Ferreira, Javed Butler, et al.
European Journal of Heart Failure|August 25, 2023
Baseline characteristics of patients enrolled in the EMPACT-MI trialJosephine Harrington, Jacob A Udell, W Schuyler Jones, et al.
European Journal of Heart Failure|March 2, 2026
Proteomic patterns according to ejection fraction: an EMPEROR-programme analysisJoão Pedro Ferreira, Francesco Fioretti, Mikhail Sumin, et al.
European Journal of Heart Failure|March 5, 2024
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programmeJoão Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
European Journal of Heart Failure|April 8, 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programmeJoão Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
Nature Cardiovascular Research|June 13, 2025
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarctionRahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, et al.
European Journal of Heart Failure|November 15, 2023
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR programJoão Pedro Ferreira, Milton Packer, Javed Butler, et al.
European Journal of Heart Failure|December 1, 2023
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trialsJoão Pedro Ferreira, Javed Butler, Stefan D Anker, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
JACC. Heart Failure|March 5, 2023
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled AnalysisJoão Pedro Ferreira, Faiez Zannad, Javed Butler, et al.
American Heart Journal|May 20, 2022
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trialJosephine Harrington, Jacob A Udell, W Schuyler Jones, et al.
European Heart Journal|August 26, 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programmeFaiez Zannad, João Pedro Ferreira, Javed Butler, et al.
European Journal of Heart Failure|August 25, 2023
Baseline characteristics of patients enrolled in the EMPACT-MI trialJosephine Harrington, Jacob A Udell, W Schuyler Jones, et al.
European Journal of Heart Failure|March 2, 2026
Proteomic patterns according to ejection fraction: an EMPEROR-programme analysisJoão Pedro Ferreira, Francesco Fioretti, Mikhail Sumin, et al.
European Journal of Heart Failure|March 5, 2024
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programmeJoão Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
European Journal of Heart Failure|April 8, 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programmeJoão Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
Nature Cardiovascular Research|June 13, 2025
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarctionRahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, et al.
European Journal of Heart Failure|November 15, 2023
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR programJoão Pedro Ferreira, Milton Packer, Javed Butler, et al.
European Journal of Heart Failure|December 1, 2023
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trialsJoão Pedro Ferreira, Javed Butler, Stefan D Anker, et al.
Pageof 2